Alto Neuroscience’s Post

Did you miss our recent webinar on "Efficiently Driving Protein-based #NMR Fragment Screening and Lead Discovery" ? Dr. Andrew “Dru” Namanja, Principal Research Scientist at AbbVie, explored the potency ranking methods involving both qualitative single-point ligand concentration (Q Score) and quantitative binding affinity (KD), and how the combined utility can be used successfully to drive a Fragment-Based Drug Discovery (#FBDD) campaign. If you missed any part of it, no worries! You can catch the recorded session here: https://lnkd.in/d9RfpXfs #dataautomation #FragmentBasedDrugDiscovery #Mnova #Mestrelab

The ultimate fate of any platform/tech-for-bio company: drug development. From 23andMe to Recursion to Atomwise and Schrodinger, making drugs seems to be the "state of lowest energy" (or highest value) in the business landscape of biopharma. But is this deep vertical integration really what's best for the industry? https://lnkd.in/eBQ-BfdZ #drugDiscovery #drugDevelopment #biotech #techForBio #techBio

[Microbiome & Drug Development] In this interview, discover how Patrick Jimonet led and united over thirty prominent international experts to develop proposals aimed at facilitating the integration of the microbiome into drug discovery. 💊 Read the interview here 👉 https://buff.ly/3zCdMDk

#SparkOfAges In this clip, host Rajiv Parikh and guest Ashwin Gopinath start to explore the details of how Biostate AI can address drug safety, focusing on the #omics involved in drug development. With R&D for new drug development already costing hundreds of millions of dollars, and potentially much more, depending on failure and the inclusion of capital costs - understanding the safety of these compounds can have a significant impact on the industry and the patients who take these drugs. Listen to the full episode here: https://spoti.fi/3SJuJTm #DrugDevelopment #Safety #Research #Development

Out Now! The June edition of our Pharma Tech Focus Digital Magazine is now live. Almost one year ago, Brazilian president Lula da Silva assembled the first South American summit in nearly a decade to gather the continent’s nations onto a single forum to encourage pharmaceutical trade. In this month’s cover story, we take a look at the progress made since then and identify the main priorities for the public and private pharma sectors in South America. Also in this issue, we continue to follow the opioid crisis in the US, by understanding the nature of the multibillion dollar settlements made by companies implicated in the crisis to several state governments. Now that the legal settlements have been finalised, the next question remains on how to distribute these funds in the best way possible to address the ongoing challenges with those suffering from opioid use disorder. Don’t miss coverage on the burgeoning cell and gene therapy landscape in the US, the challenges with sham patents, and much more.  - https://lnkd.in/g-GSuTCM Also you will find insights from our partners Mimotopes, phasetwo®, Datwyler Healthcare, Xylem, Cytiva and Bea Technologies SpA If you would like information about advertising in future editions please send us a message and a member of the team will get in touch. #pharma #clinicaltrials #opiods #bioprocessing #esg #celltherapy #genetherapy #cellandgene #biotech #biopharma #cdmo #cro

At LAXAI, we are dedicated to advancing drug discovery and development. Here’s a glimpse into our case study on how we addressed pharmacokinetic and pharmacodynamic challenges to enhance drug delivery and therapeutic action through prodrugs. By designing innovative prodrugs, we improved lead compound properties such as solubility, metabolic stability, permeability and eventually efficacy to achieve a new benchmark in prodrug development. Contact us at bd@laxai.com or visit www.laxai.com to know more about our drug discovery and development solutions. Kishore V Renduchintala Ganesh Venkatraman Ramesh Mullangi James Schwindeman, Ph.D. Rama Mohan Kolli Vidya Sagar K Yogesh Munot #LAXAI #SmallMolecules #CRDMO #CaseStudy #Prodrug #DrugDevelopment

Thoughts on this? >> Cartesian clears an autoimmune CAR-T trial, starts another Phase 2 and raises $130M >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #pharma #productmarketing #pharmaceutical #healthcare

Strong evidence of the importance and power of Tscm !!.

ICYMI: Recent research highlights the critical role of N-terminal acetylation by N-terminal acetyltransferases (NATs) in shaping protein lifespan. This insight offers promising pathways for targeted drug development. Read more on our blog: https://lnkd.in/eTrMXHzU

Predicting the properties of new drug candidates can save millions of dollars and years of development. Learn more about the critical trends to watch in our webinar on Jan. 25 at 10:30 a.m. EDT with experts from Lawrence Livermore National Laboratory and Oak Ridge National Laboratory. Register: https://ow.ly/cqeT50QqoI4 #AI #pharma #2024trends